Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02250534 · ClinicalTrials.gov registry record · Phase 1
Project 1, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Childbearing Age Women
A Phase 1 study, sponsored by University of Vermont.
- Completed
- Registry status
- Phase 1
- Development phase
- 775
- Enrollment target
NCT02250534 is a Phase 1 study that has completed, run by University of Vermont. The registered enrollment target is 775 participants.
The verdict
NCT02250534, a Phase 1 study, has completed, sponsored by University of Vermont.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 775 participants
- Enrollment target
Study Summary
This study will examine extended exposure to cigarettes varying in nicotine content among disadvantaged women. Disadvantaged women are at increased risk for smoking, nicotine dependence, and using high nicotine yield cigarettes and are also at significantly increased risk for smoking-related adverse health consequences, including cervical cancer, thrombosis related to hormone-based contraception, infertility, and early menopause. Studies testing an innovative regulatory strategy of reducing the nicotine content of cigarettes to a non-addictive level have shown promising beneficial effects (decreased smoking rate, reduced toxicant exposure, and increased cessation) in the general population of smokers. However, these studies have uniformly excluded vulnerable populations like disadvantaged women who may respond differently considering their greater vulnerability to smoking and nicotine dependence. Thus, little is known scientifically about how this highly vulnerable subgroup of smokers might respond to a nicotine reduction policy. This project is designed to address that substantial knowledge gap. This same study was also conducted in two additional vulnerable populations under a similar protocol.
Interventions
- OTHER Very low nicotine content cigarettes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 775 participants |
| Start Date | 2016-10 |
| Est. Completion | 2019-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02250534
The ClinicalTrials.gov registry entry for NCT02250534 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 775 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Vermont, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Very low nicotine content cigarettes is the first listed.
NCT02250534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02250534 about?
NCT02250534 is a clinical study titled "Project 1, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Childbearing Age Women". This study will examine extended exposure to cigarettes varying in nicotine content among disadvantaged women. Disadvantaged women are at increased risk for smoking, nicotine dependence, and using high nicotine yield cigarettes and are also at significantly increased risk for smoking-related adverse...
What is the current status of trial NCT02250534?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 775 participants. The study started on 2016-10. Estimated completion is 2019-10.
What interventions are being tested in trial NCT02250534?
The interventions under investigation include: Very low nicotine content cigarettes (OTHER).
Who is sponsoring clinical trial NCT02250534?
This trial is sponsored by University of Vermont, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.